INTRODUCTION
Parkinson's disease (PD; MIM 168600) is the second most common neurodegenerative disorder, presently affecting more than a million people in the USA. Clinically, the disease is characterized by symptoms including resting tremor, bradykinesia and rigidity, due to the specific loss of pigmented dopaminergic neurons in the substantia nigra (1) . Recent evidence has suggested that genetic components may be important in familial early-onset parkinsonism as well as in more typical, idiopathic PD (2) (3) (4) (5) (6) .
Deletions/duplications and point mutations in the parkin gene were originally associated with autosomal recessive juvenile parkinsonism (AR-JP), without Lewy body pathology (7) . Compound heterozygous mutations have since been identified in cases resembling typical late-onset PD (2, 8) , and in a single case with Lewy bodies observed on postmortem examination (9) . In addition, apparently dominant families have been described with only a single parkin mutation in affected cases (9) (10) (11) (12) (13) (14) . Subsequently, several studies have hypothesized that loss of parkin expression due to haploinsufficiency may be a risk factor for dopaminergic cell death. Of note, in one family, [ 18 F]fluorodopa positron emission analysis of parkin mutation carriers was also suggestive of dopaminergic loss compatible with presymptomatic disease (10, 14) .
With this background, we hypothesized that reduced rather than completely ablated parkin gene function could confer risk for idiopathic PD. Polymorphic variability within a gene promoter can effect gene expression and has previously been associated with age-associated neurodegeneration (15) (16) (17) . Recently, nine single-nucleotide polymorphisms (SNPs) have been described in the parkin promoter (11) . Two of these SNPs reside within the parkin core promoter, which is the region in the parkin gene identified as possessing the majority of transcription regulation (18, 19) . In the present study, we describe a genetic association of idiopathic PD with the À258 T/G promoter SNP in a large, clinically well-characterized case/ control series. Further, we demonstrate this SNP occurs within a nuclear protein-binding site and affects transcription.
RESULTS
We previously described nine SNPs in the parkin gene promoter and their heterogeneity in Northern Europeans (11) . Two of the nine polymorphisms (À258 T/G and À227 A/G) lie within the parkin core promoter, i.e. the minimum region of DNA upstream of parkin exon 1 that contains full transcription activation in neuroblastoma cells. These SNPs were genotyped in a population-based series of PD cases and controls; both were in Hardy-Weinberg equilibrium (not shown). Genotype distributions of the À227 A/G SNP were not significantly different between PD cases and controls. However, the À258 SNP, specifically the À258 G allele, demonstrated some evi-*To whom correspondence should be addressed. Tel: þ1 9049530158; Fax: þ1 9049537370; Email: farrer.matthew@mayo.edu dence of association with disease [odds ratio (OR) ¼ 1.52, 95% confidence interval (CI) ¼ 1.03-2.28, P ¼ 0.04; Table 1 ]. There was no difference between subgroups divided by gender or family history (data not shown). However, stratifying PD cases by median age (71 years) showed a significant association with the older-onset group (>71 years).
To assess the functional potential of genetic variability in the parkin core promoter, we used in silico sequence analysis (20) for DNA-binding domains about the À258 and À227 SNP regions. Using MatInspector v2.2 (http://transfac.gbf.de/), no protein-binding sites were predicted near the À227 SNP; however, the À258 SNP is located in a consensus domain for an NF1-like binding site. A 'T' at position À258 generates an NF1-like site with a MatInspector core similarity of 1.00 and an affinity of 0.935, whereas a 'G' at position À258 generates a core similarity of 0.748 and an affinity score of 0.745 (against the NF1 transcription factor-binding matrix). Thus, in silico results suggested that the À258 T allele was more likely to bind NF1-like proteins than the À258 G allele.
A literature search revealed that the NF1-like sequence consensus motif located in the parkin promoter, TTGGC, has been previously described to regulate the transcription of the Ca 2þ -binding protein regucalcin gene (21) . Located $500 bp upstream of the transcription start, artificial mutations in TTGGC resulted in a 20% decrease in the rate of transcription. This motif has also been shown to bind nuclear protein from multiple cell lines (22) . We hypothesized that the TTGGC motif may also bind protein derived from human substantia nigra, and could be important in the regulation of the parkin gene. To examine this possibility, we utilized electromobility shift assays (EMSA) to determine the protein-binding affinity of the TTGGC motif found in the parkin core promoter. The labeled probe (depicted in Fig. 1 ) was shifted when incubated with nuclear protein derived from human substantia nigra ( Fig. 2: lane 2) ; similar results were obtained with nuclear protein derived from M17 and HEK nuclear protein extracts (data not shown).
To determine the effect of the À258 T/G allele on protein binding, we used a competition assay to measure the effectiveness of the two alleles as competitors for protein binding. Specificity of the protein-probe interaction is suggested by the reduction of the shifted complex upon addition of unlabeled probe. Both the T and G allele-specific probes completely competed away the shifted complex at a 40-molar excess to labeled T allele probe. However, at lower concentrations of competitor probe, the G allele did not compete the shifted complex as efficiently as the T allele, suggesting that the À258 T-to-G alteration may reduce nuclear protein-binding affinity. This is illustrated in Fig. 2 , as a 5-fold excess of the T allele competes away the complex similarly to a 40-fold excess of the G allele. Results were typical of multiple experiments.
To determine the in vivo effects of the À258 T/G allele on transcription regulation, we cloned allele-specific promoter fragments ( Fig. 1) into the pGL3-Basic vector (Promega). A knockout promoter fragment was also designed with multiple mutations across the consensus TTGGC NF1-A1-binding motif (Fig. 3) , which have been previously shown to negate interactions with nuclear protein (21) . Promoter activity was assayed using a dual-luciferase system (Promega), and compared relative to SV40 control promoter activity. Of note, the À258 G allele reduced luciferase activity by $25% relative to the À258 T allele. The NF1-A1 knockout vector also reduced luciferase activity by $25%, illustrating the importance of the À258 nucleotide regarding transcription regulation (Fig. 3) . Allele-specific constructs were also designed for the À227 A/G SNP; however, no differences in luciferase activity were observed (data not shown).
DISCUSSION
Recessive and compound heterozygous mutations in the parkin gene clearly cause early-onset parkinsonism. However, the relationship of parkin variability to idiopathic, Lewy body PD remains obscure. Initial studies of parkin coding polymorphisms suggested an association with PD (23) (24) (25) , but these early studies have been difficult to reproduce (26, 27) . There are a number of possible confounders, including clinical, locus and allelic heterogeneity in the populations under study (28) . Criteria to improve replication validity have been proposed (29); however, functional analysis of allelic variability might demonstrate a direct effect on gene/protein expression. The position of the parkin promoter and SNPs within this region have been previously described (11, 18) . We evaluated two of these SNPs based on their location in the parkin core promoter for association with idiopathic PD in a clinically well-defined series of idiopathic PD cases versus controls. While the À227 SNP showed no difference between cases and controls, the À258 G allele was subsequently found to be over-represented in PD cases (>71 years). In silico analysis also predicted the SNP at À258 to affect protein binding, while the SNP at À227 was not predicted to be near a known protein-binding domain.
Gel-shift experiments (EMSA) verified that sequence about the À258 nucleotide binds nuclear protein derived from human substantia nigra. Whether the À258 NF1-A1 consensus site is occupied in the parkin promoter in vivo remains to be determined (specific antibodies to this protein were not available for competition experiments). However, dual-luciferase measurements confirmed that À258 T/G allelic differences affect parkin gene expression in transient transfection assays.
This study provides the first functional evidence implicating parkin promoter SNP variability in gene expression. Furthermore, the data support a genetic association with lateonset Parkinson's disease. The À258 G allele was observed in 19% of controls and 25% of late-onset PD cases (>71 years). These findings are consistent with a previous study of in which the À258 G allele was observed in 14% of Northern European controls and in 61% (11/18) of alleles inherited by heterozygous parkin carriers (OR ¼ 9.7, 95% CI ¼ 2.8-33.9, P < 0.001) (11) . When inherited in trans, the À258 G allele associated with reduced parkin expression may also contribute to earlyonset parkinsonism in carriers with a parkin mutation.
MATERIALS AND METHODS

Patients with Parkinson's disease and controls
Cases with PD and controls were derived from an ongoing study of the epidemiology and genetics of PD at Mayo Clinic Rochester (30, 31) . A total of 319 unrelated PD patients and 196 controls who provided blood samples were included in this study. The majority of PD patients (n ¼ 278; 87%) were sequential new referrals to the Department of Neurology, between July 1996 and May 1999, and were all residents of Minnesota or the surrounding four states (Wisconsin, Iowa, South Dakota and North Dakota). Forty-one additional patients (13%) were recruited through an incidence study of PD in the Olmsted County, Minnesota, population. Controls were either spouses of patients free of PD at the time of the study (n ¼ 150; 77%) or subjects free of PD from the same population (n ¼ 46; 23%).
All subjects were examined using a standardized clinical protocol by one of three movement disorders specialists (Drs D. M. Maraganore, J. E. Ahlskog and J. H. Bower of the Mayo Clinic) and had at least two of four cardinal signs (bradykinesia, rigidity, rest tremor and postural instability). Subjects with no or minimal improvement from levodopa (in combination with carbidopa) at doses >1 g/day were excluded. We also excluded patients with other causes of parkinsonism, or with unexplained signs of more extensive neurological involvement (dementia or mild dysautonomia were allowed if they occurred after the first year of motor symptoms).
This study was approved by the Mayo Institutional Review Board, and informed consent was obtained from each subject at the time of blood drawing. All laboratory tests were performed by an investigator kept unaware of the case-control assignment of subjects. Blood samples were processed via the Purgene procedure (Gentra Systems, Inc., Minneapolis, MN) to extract DNA.
Genetic analysis
SNPs were determined using a standard RFLP protocol, first amplifying 25 ng of patient genomic DNA (primers: forward 5 0 -GCATTTGTTTAAGCTCAGGGTCTC-3 0 and reverse 5 0 -CCTGCTGGGAGTCGTAGTTCTAAC-3 0 for the À258 and À227 variants) using a 60-50 C touchdown protocol over 35 cycles. PCR products were then digested with a restriction Figure 1 . A schematic representation of the parkin core promoter. The parkin exon 1 is shown as bold sequence, with the parkin start codon highlighted (doubleunderlined). The two SNPs in this region are indicated with stars and the DNA sequence used as an EMSA probe is boxed. The positions of the primers used to generate the luciferase constructs are overlined.
enzyme (StuI for the À227 variant and AlwNI for the À258 variant; New England Biolabs) ( Table 1) . Digested products were analyzed on 3% agarose gels, stained with ethidium bromide.
Statistical analysis
The association of the candidate gene with PD was measured by ORs, which closely approximate the relative risk in rare disease. Because more men were included among cases and more women among controls, ORs were adjusted for sex using logistic regression models (32) . Similarly, ORs were adjusted for age at examination (time of the study) where appropriate. For each OR, a 95% CI was computed, and a two-sided statistical test was performed at an a-level of 0.05. Analyses restricted to subjects with both parents of European origin were conducted to reduce the risk of population stratification bias. Analyses stratified by age at examination, gender (not shown) and family history (not shown) were also performed. All analyses were performed using SAS software (Cary, NC).
Electromobility shift assays (EMSA)
Nuclear protein was derived from human fresh-frozen substantia nigra tissue (courtesy of Dr Deborah Mash and the University of Miami/National Parkinson's Foundation Brain Endowment Bank) using the Sigma Nu-CLEAR kit (Sigma Life Sciences), according to the suggested protocol. Probes to detect the À258 SNP were made by Invitrogen (forward for the À258 G variant) and cartridge-purified to select for full-length oligonucleotides. The two À258 variant-specific double-stranded oligonucleotides were generated by heating the complementary oligonucleotides in a high-salt solution (10 mM Tris-HCl, pH 7.5, 1 mM EDTA and 100 mM NaCl) at 65 C for 15 min, and then allowed to cool to room temperature. Doublestranded DNAs were labeled using [g-32 P]dATP (3000 mCi/ mmol, NEN) and T4 polynucleotide kinase (Promega), and radioactivity was counted by liquid scintillation. The Gel-Shift Assay system (Promega) was employed, following the manufacturer's protocol, and allele-specific competition reactions were carried out in tandem. Products were electrophoresed in Novex 6% DNA retardation gels, in 0.5Â TBE running buffer at 100 V, and gels were dried and visualized using Kodak Biomax film with one intensifier screen at À70 C overnight.
Construction of luciferase vectors
Three parkin core promoter constructs, containing the À258 T allele, the À258 G allele or an NF1-A1 consensus site knockout (21), were amplified from BAC DNA containing parkin exon 1, using primers with internal restriction sites for cloning (forward 5 0 -GGAAGAGGTACCGACCTTGGCTA-3 0 for the À258 T allele, forward 5 0 -GGAAGAGGTACCGACCTGG-GCTA-3 0 for the À258 G allele, forward 5 0 -GGGAAGAGGTA-CCGACCTGTTGTA-3 0 for the NF1-A1 knockout mutant and reverse 5 0 -CGTGTTGACCAGTCGCTAGCCA-3 0 ) (Fig. 1) . PCR was performed using a 65-55 C touchdown protocol, with Taq DNA polymerase (Qiagen) and 1 ng of BAC DNA. PCR products and the pGL3-Basic vector (Promega) were digested with KpnI and NheI (Roche Biochemicals) and purified (Qiagen), according to the manufacturers' conditions. Vector arms were Figure 2 . Electromobility shift assay (EMSA) about the À258 polymorphism using allele-specific probes. Lane 1, no nuclear extract (probe alone); lanes 2-16, 5 mg of human substantia nigra nuclear protein extract. Unlabeled competitor allele-specific probe was added to lanes 3-9 (T allele) and lanes 10-16 (G allele).
dephosphorylated (CIP; Promega) and ligated to digested PCR fragments (DNA Rapid Ligation Kit; Roche Biochemicals). Constructs were subcloned into DH5a cells (Life Technologies), single colonies were miniprepped (Qiagen) and the insert was verified by sequence analysis.
Plasmid transfection and luciferase assay
Human dopaminergic neuroblastoma BE(2)-M17 cells and human embryonic kidney cells (HEK-293T) were cultured in Opti-MEM (Life Technologies) supplemented with 10% FBS, penicillin (100 units/ml) and streptomycin (100 mg/ml). Cells were plated 24 h prior to transfection into 24-well culture plates at 80% confluence and maintained in an atmosphere of 5% CO 2 at 37 C. Transfection was performed with Fugene (Roche Biochemicals), using 0.2 mg of DNA per well, in a 1 : 3 ratio of DNA : Fugene reagent, and added to cells in serum-free media for 12 h.
Luciferase-containing constructs (pGL3) were co-transfected with phRL-TK synthetic renilla vector (Promega) to control for transfection efficiency, in a molar ratio of 1 : 100 (phRL-TK versus pGL3). Forty hours after transfection, cells were gently rinsed with PBS and then harvested with Passive Lysis buffer (Promega). The Dual Luciferase system (Promega) was used according to the manufacturer's protocol, and experiments were repeated in six independent wells. Readings were taken in duplicate on a Turner Designs 20/20 Single Injector Luminometer.
